Percutaneous penetration enhancement and its quantification

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 46, Issue 1, 1998, Pages 1-13

  Bach, Monika ^a   Lippold, Bernhard C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Activity response curves; In vivo; Penetration enhancement; Thermodynamic activity; Transdermal drug delivery

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ACICLOVIR; ALCOHOL; BETAMETHASONE; BUPRENORPHINE; DITHIOTHREITOL; FATTY ACID ESTER; FATTY ALCOHOL; LAURIC ACID; LAUROCAPRAM; LIDOCAINE; LIMONENE; MYRISTIC ACID; MYRISTIC ACID ISOPROPYL ESTER; NAFARELIN; NICOTINIC ACID ETHYL ESTER; NICOTINIC ACID METHYL ESTER; NORADRENALIN; OLEIC ACID; PENETRATION ENHANCING AGENT; PIROXICAM; SALICYLIC ACID; SOLVENT; SPHINGOLIPID; TERPENE; TOLAZOLINE; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

DRUG DIFFUSION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; IONTOPHORESIS; LIPOPHILICITY; MAMMAL; MEMBRANE FLUIDITY; MOUSE; NONHUMAN; PARTITION COEFFICIENT; RAT; REVIEW; SKIN ABSORPTION; SKIN PENETRATION; SKIN PERMEABILITY; STRATUM CORNEUM; THERMODYNAMICS;

EID: 0032443378     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(97)00149-5     Document Type: Article

References (172)

1. Guy R.H., Hadgraft J. Transdermal drug delivery: the ground rules are emerging. Pharm. Int. 6:1985;112-116.
2. Tojo K., Keshary P.R., Chien Y.W. Drug permeation through skin from matrix-type drug delivery systems. Chem. Eng. J. 32:1986;B57-B64.
3. Chien Y.W., Keshary P.R., Huang Y.C., Sarpotdar P.P. Comparative controlled skin permeation of nitroglycerin from marketed transdermal delivery systems. J. Pharm. Sci. 72:1983;968-970.
4. G.L. Flynn, Physicochemical determinants of skin absorption, in: T.R. Gerrity, C.J. Henry (Eds.), Principles of Route-to-Route Extrapolation for Risk Assessment, Elsevier, Amsterdam, 1990, pp. 93-127.
5. V.-H. Le, Einfluß von Substanzeigenschaften auf Permeabilität und maximalen Flux von homologen Nicotinsäureestern in vitro and an der Haut in vivo. Ph.D. Thesis, Düsseldorf, 1993.
6. Hagedorn-Leweke U., Lippold B.C. Absorption of sunscreens and other compounds through human skin in vivo: derivation of a method to predict maximum fluxes. Pharm. Res. 12:1995;1354-1360.
7. Le V.H., Lippold B.C. Influence of physicochemical properties of homologous esters of nicotinic acid on skin permeability and maximum flux. Int. J. Pharm. 124:1995;285-292.
8. R.H. Guy, J. Hadgraft, Selection of drug candidates for transdermal drug delivery, in: J. Hadgraft, R.H. Guy (Eds.), Transdermal Drug Delivery, Marcel Dekker, New York, 1989, pp. 59-81.
9. Chien Y.W. Transdermal systemic drug delivery. Recent development and future prospects. S.T.P. Pharma Sci. 1:1991;5-23.
10. K.A. Walters, Penetration enhancers and their use in transdermal therapeutic systems, in: J. Hadgraft, R.H. Guy (Eds.), Transdermal Drug Delivery, Marcel Dekker, New York, 1989, pp. 197-246.
11. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J. Soc. Cosmet. Chem. 11:1960;85-97.
12. Woodford R., Barry B.W. Optimization of bioavailability of steroids: thermodynamic control. J. Invest. Dermatol. 79:1982;388-391.
13. Lippold B.C. How to optimize drug penetration through the skin. Pharm. Acta Helv. 67:1992;294-300.
14. Lippold B.C., Reimann H. Wirkungsbeeinflussung bei Lösungssalben durch Vehikel am Beispiel von Methylnicotinat. Teil II: Beziehung zwischen relativer thermodynamischer Aktivität and Bioverfügbarkeit: Penetrationsbeschleunigung and Entleerungseffekt. Acta Pharm. Technol. 35:1989;136-142.
15. Lippold B.C., Schneemann H. The influence of vehicles on the local bioavailability of betamethasone-17-benzoate from solution- and suspension-type ointments. Int. J. Pharm. 22:1984;31-43.
16. Koyama Y., Bando H., Yamashita F., Takakura Y., Sezaki H., Hashida M. Comparative analysis of percutaneous absorption enhancement by d-limonene and oleic acid based on a skin diffusion model. Pharm. Res. 11:1994;377-383.
17. Kobayashi D., Matsuzawa T., Sugibayashi K., Morimoto Y., Kimura M. Analysis of the combined effect of 1-menthol and ethanol as skin permeation enhancers based on a two-layer skin model. Pharm. Res. 11:1994;96-103.
18. Okamoto H., Hashida M., Sezaki H. Effect of 1-alkyl- or 1-alkenylazacycloalkanone derivatives on the penetration of drugs with different lipophilicities through guinea pig skin. J. Pharm. Sci. 80:1991;39-45.
19. Kim C.K., Kim J.-J., Chi S.-C., Shim C.-K. Effect of fatty acids and urea on the penetration of ketoprofen through rat skin. Int. J. Pharm. 99:1993;109-118.
20. Lee C.K., Uchida T., Noguchi E., Kim N.-S., Goto S. Skin permeation enhancement of tegafur by ethanol/panasate 800 or ethanol/water binary vehicle and combined effect of fatty acids and fatty alcohols. J. Pharm. Sci. 82:1993;1155-1159.
21. Shah H.S., Tojo K., Chien Y.W. Enhancement of in vitro permeation of verapamil. Drug Dev. Ind. Pharm. 18:1992;1461-1476.
22. Williams A.C., Barry B.W. Terpenes and the lipid-protein-partioning theory of skin penetration enhancement. Pharm. Res. 8:1991;17-24.
23. Takayama K., Kikuchi K., Obata Y., Okabe H., Machida Y., Nagai T. Terpenes as percutaneous absorption enhancers. S.T.P. Pharma Sci. 1:1991;83-88.
24. Doucet O., Hagar H., Marty J.P. Enhancement of indomethacin percutaneous absorption. Effect of 2-n-nonyl-1,3-dioxolane. S.T.P. Pharma Sci. 1:1991;89-93.
25. Pershing L.K., Parry G.E., Lambert L.D. Disparity of in vitro and in vivo oleic acid-enhanced β-Estradiol percutaneous absorption across human skin. Pharm. Res. 10:1993;1745-1750.
26. Leopold C.S., Lippold B.C. Enhancing effects of lipophilic vehicles on skin penetration of methyl nicotinate in vivo. J. Pharm. Sci. 84:1995;195-198.
27. Bennett S.L., Barry B.W., Woodford R. Optimization of bioavailability of topical steroids: non-occluded penetration enhancers under thermodynamic control. J. Pharm. Pharmacol. 37:1985;298-304.
28. Barry B.W., Southwell D., Woodford R. Optimization of bioavailability of topical steroids: penetration enhancers under occlusion. J. Invest. Dermatol. 82:1984;49-52.
29. Lippold B.C., Teubner A. Biopharmazeutische Qualität von Arzneiformen, insbesondere für lokale Anwendung, abgeleitet aus Wirkungsmessungen. Pharm. Ind. 43:1981;71-73.
30. Scheuplein R.J. Mechanism of percutaneous absorption. I. Routes of penetration and the influence of solubility. J. Invest. Dermatol. 45:1965;334-346.
31. B.J. Poulsen, Diffusion of drugs from topical vehicles: an analysis of vehicle effects, in: W. Montagna, E.J. van Scott, R.B. Stoughton (Eds.), Advances in Biology of Skin, Vol. XII, Pharmacology and the Skin, Appleton-Century-Crofts, New York, 1972, pp. 495-509.
32. Scheuplein R.J., Blank I.H. Permeability of the skin. Physiol. Rev. 51:1971;702-747.
33. B.C. Lippold, Biopharmazie. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1984, pp. 99-131.
34. Barry B.W. Mode of action of penetration enhancers in human skin. J. Control. Release. 6:1987;85-97.
35. Elias P.M., Cooper E.R., Korc A., Brown B.E. Percutaneous transport in relation to stratum corneum structure and lipid composition. J. Invest. Dermatol. 76:1981;297-301.
36. Smith W.P., Christensen M.S., Nacht S., Gans E.H. Effect of lipids on the aggregation and permeability of human stratum corneum. J. Invest. Dermatol. 78:1982;7-11.
37. Potts R.O., Guy R.H. Lipids alone account for stratum corneum permeability. J. Invest. Dermatol. 96:1991;580.
38. Anderson B.D., Raykar P.V. Solute-permeability relationship in human stratum corneum. J. Invest. Dermatol. 93:1989;280-286.
39. Ziegenmeyer J. Transdermale Applikation von Arzneistoffen. Pharm. Ztg. 18:1989;1085-1091.
40. Lauer A.C., Lieb L.M., Ramachandran C., Flynn G.L., Weiner N.D. Transfollicular drug delivery. Pharm. Res. 12:1995;179-186.
41. Liu P., Nightingale J.A.S., Kurihara-Bergstrom T. Variation of human skin permeation in vitro: ionic vs neutral compounds. Int. J. Pharm. 90:1993;171-176.
42. Cornwell P.A., Barry B.W. The routes of penetration of ions and 5-fluorouracil across human skin and the mechanisms of action of terpene skin penetration enhancers. Int. J. Pharm. 94:1993;189-194.
43. Ruland A., Rohr U., Kreuter J. Transdermal delivery of the tetrapeptide hisetal (melanotropin (6-9)) and amino acids: their contribution to the elucidation of the existence of an 'aqueous pore' pathway. Int. J. Pharm. 107:1994;23-28.
44. Bando H., Yamashita F., Takahura Y., Hashida M. Skin penetration enhancement of acyclovir by prodrug-enhancer combination. Biol. Pharm. Bull. 17:1994;1141-1143.
45. Hueber F., Schaefer H., Wepierre J. Role of transepidermal and transfollicular routes in percutaneous absorption of steroids: in vitro studies on human skin. Skin Pharmacol. 7:1994;237-244.
46. Scott E.R., Laplaza A.I., White H.S., Phipps J.B. Transport of ionic species in skin: contribution of pores to the overall skin conductance. Pharm. Res. 10:1993;1699-1709.
47. Hatanaka T., Manabe E., Sugibayashi K., Morimoto Y. An application of the hydrodynamic pore theory to percutaneous absorption of drugs. Pharm. Res. 11:1994;654-657.
48. Peck K.D., Ghanem A.-H., Higuchi W.I. Hindered diffusion of polar molecules through and effective pore radii estimates of intact and ethanol treated human epidermal membrane. Pharm. Res. 11:1994;1306-1314.
49. 2 transport through human skin in vitro. Int. J. Pharm. 53:1989;13-24.
50. de Haan F.H.N., Boddé H.E., de Bruijn W.C., Ginsel L.A., Junginger H.E. Visualizing drug transport across stram corneum: cryotechniques, vapour fixation, autoradiography. Int. J. Pharm. 56:1989;75-86.
51. Kadir R., Stempler D., Liron Z., Cohen S. The delivery of theophylline into excised human skin from alkanoic acids solution: a 'push-pull' mechanism. J. Pharm. Sci. 76:1987;774-779.
52. Kadir R., Stempler D., Liron Z., Cohen S. Penetration of adenosine into excised human skin from binary vehicles: the enhancement factor. J. Pharm. Sci. 77:1988;409-413.
53. R. Kadir, M. Ponec, H.L.G.M. Tiemessen, H.E. Junginger, H.E. Boddé, Oleyl surfactants as skin penetration enhancers: effects on human stratum corneum permeability and in vivo toxicity to cultured human skin cells, in: K.A. Walters, J. Hadgraft (Eds.), Pharmaceutical Skin Penetration, Marcel Dekker, New York, 1993, pp. 215-227.
54. Lippold B.C., Reimann H. Wirkungsbeeinflussung bei Lösungssalben durch Vehikel am Beispiel von Methylnicotinat. Teil I: Relative thermodynamische Aktivität des Arzneistoffes in verschiedenen Vehikeln and Freisetzungsverhalten. Acta Pharm. Technol. 35:1989;128-135.
55. H. Reimann, Vehikeleffekte bei Methylnicotinat-Lösungssalben. Ph.D. Thesis, Düsseldorf, 1986.
56. Flynn G.L., Stewart B. Percutaneous drug penetration: choosing candidates for transdermal development. Drug Dev. Res. 13:1988;169-185.
57. Okamoto H., Muta K., Hashida M., Sezaki H. Percutaneous penetration of acyclovir through excised hairless mouse and rat skin: effect of vehicle and percutaneous penetration enhancer. Pharm. Res. 7:1990;64-68.
58. Kurosaki Y., Nagahara N., Tanizawa T., Nishimura H., Nakayama T., Kimura T. Use of lipid disperse systems in transdermal drug delivery: comparative study of flufenamic acid permeation among rat abdominal skin, silicon rubber membrane and stratum corneum sheet isolated from hamster cheek pouch. Int. J. Pharm. 67:1991;1-9.
59. Kubota K., Sznitowska M., Maibach H.I. Percutaneous permeation of betamethasone 17-valerate from different vehicles. Int. J. Pharm. 96:1993;105-110.
60. Michniak B.B., Chapman J.M., Seyda K.L. Facilitated transport of two model steroids by esters and amides of clofibric acid. J. Pharm. Sci. 82:1993;214-219.
61. Michniak B.B., Player M.R., Chapman J.M. Jr., Sowell J.W. Azone analogues as penetration enhancers: effect of different vehicles on hydrocortisone acetate skin permeation and retention. J. Control. Release. 32:1994;147-154.
62. Michniak B.B., Player M.R., Chapman J.M. Jr., Sowell J.W. In vitro evaluation of a series of Azone analogs as dermal penetration enhancers. Int. J. Pharm. 91:1993;85-93.
63. Ryatt K.S., Stevenson J.M., Maibach H.I., Guy R.H. Pharmacodynamic measurement of percutaneous penetration enhancement in vivo. J. Pharm. Sci. 75:1986;374-377.
64. 2 through human skin in-vitro. J. Pharm. Pharmacol. 42S:1990;86.
65. Ogiso T., Iwaki M., Tsuji S. Percutaneous absorption of bromhexine in rats. Chem. Pharm. Bull. 39:1991;1609-1611.
66. Niazy E.M. Influence of oleic acid and other permeation promoters on transdermal delivery of dihydroergotamine through rabbit skin. Int. J. Pharm. 67:1991;97-100.
67. Nomura H., Kaiho F., Sugimoto Y., Miyashita Y., Dohi M., Kato Y. Percutaneous absorption of indomethacin from mixtures of fatty alcohol and propylene glycol (FAPG bases) through rat skin: effects of oleic acid added to FAPG base. Chem. Pharm. Bull. 38:1990;1421-1424.
68. Bonina F.P., Montenegro L. Vehicle effects on in vitro heparin release and skin penetration from different gels. Int. J. Pharm. 102:1994;19-24.
69. Morimoto Y., Hatanaka T., Oguchi M., Sugibayashi K., Kobayashi M., Kimura M. A screening method for percutaneous absorption enhancers appropriate for adhesive matrix devices. S.T.P. Pharma Sci. 2:1992;253-258.
70. Obata Y., Takayama K., Maitani Y., Machida Y., Nagai T. Effect of pretreatment of skin with cyclic monoterpenes on permeation of diclofenac in hairless rat. Biol. Pharm. Bull. 16:1993;312-314.
71. Goodman M., Barry B.W. LPP theory of skin enhancer activity: finite dose technique. Int. J. Pharm. 57:1989;29-40.
72. Barry B.W. LPP theory of skin penetration enhancement. J. Control. Release. 15:1991;237-248.
73. Bouwstra J.A., Peschier L.J.C., Brussee J., Boddé H.E. Effect of N-alkyl-azocycloheptan-2-ones including Azone on the thermal behaviour of human stratum corneum. Int. J. Pharm. 52:1989;47-54.
74. Mak V.H.W., Potts R.O., Guy R.H. Oleic acid concentration and effect in human stratum corneum: non-invasive determination by attenuated total reflectance infrared spectroscopy in vivo. J. Control. Release. 12:1990;67-75.
75. Golden G.M., McKie J.E., Potts R.O. Role of stratum corneum lipid fluidity in transdermal drug flux. J. Pharm. Sci. 76:1987;25-28.
76. Kadir R., Barry B.W. α-Bisabolol, a possible safe penetration enhancer for dermal and transdermal therapeutics. Int. J. Pharm. 70:1991;87-94.
77. Leopold C.S., Lippold B.C. An attempt to clarify the mechanism of the penetration enhancing effects of lipophilic vehicles with differential scanning calorimetry (DSC). J. Pharm. Pharmacol. 47:1995;276-281.
78. Potts R.O., Francoeur M.L. Lipid biophysics of water loss through the skin. Proc. Natl. Acad. Sci. USA. 87:1990;3871-3873.
79. Scheuplein R.J. Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of the skin. J. Invest. Dermatol. 48:1967;79-88.
80. Hadgraft J., Rideout G. Development of model membranes for percutaneous absorption measurements I. Isopropyl myristate. Int. J. Pharm. 39:1987;149-156.
81. Albery W.J., Hadgraft J. Percutaneous absorption: in vivo experiments. J. Pharm. Pharmacol. 31:1979;140-147.
82. Albery W.J., Hadgraft J. Percutaneous absorption: theoretical description. J. Pharm. Pharmacol. 31:1979;129-139.
83. Lange-Lieckfeld R., Lee G. Use of a model lipid matrix to demonstrate the dependence of the stratum corneum's barrier properties on its internal geometry. J. Control. Release. 20:1992;183-194.
84. Lieckfeldt R., Lee G. Measuring the diffusional pathlength and area within membranes of excised human stratum corneum. J. Pharm. Pharmacol. 47:1995;26-29.
85. Potts R.O., Francoeur M.L. The influence of stratum corneum morphology on water permeability. J. Invest. Dermatol. 96:1991;495-499.
86. R.O. Potts, R.H. Guy, The prediction of percutaneous penetration: a mechanistic model, in: R. Gurny, A. Teubner (Eds.), Dermal and Transdermal Drug Delivery: New Insights and Perspectives, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993, pp. 153-160.
87. Lieckfeldt R., Villalain J., Gómez-Fernández J.-C., Lee G. Diffusity and structural polymorphism in some model stratum corneum lipid systems. Biochim. Biophys. Acta. 1150:1993;182-188.
88. Lippold B.C., Kurka P. Einfluß von Herstellung and Lagerung auf die Arzneistofffreisetzung aus Lösungssalben. Pharmazie. 38:1983;347-348.
89. Bouwstra J.A., Gooris G.S., Brussee J., Salomons-de Vries M.A., Bras W. The influence of alkyl-azones on the ordering of the lamellae in human stratum corneum. Int. J. Pharm. 79:1992;141-148.
90. Francoeur M.L., Golden G.M., Potts R.O. Oleic acid: its effects on stratum corneum in relation to (trans)dermal drug delivery. Pharm. Res. 7:1990;621-627.
91. Walker M., Hadgraft J. Oleic acid: a membrane 'fluidiser' or fluid within the membrane? Int. J. Pharm. 71:1991;R1-R4.
92. Ongpipattanakul B., Burnette R.R., Potts R.O., Francoeur M.L. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm. Res. 8:1991;350-354.
93. Knutson K., Krill S.L., Lambert W.J., Higuchi W.I. Physicochemical aspects of transdermal permeation. J. Control. Release. 6:1987;59-74.
94. Ongpipattanakul B., Francoeur M.L., Potts R.O. Polymorphism in stratum corneum lipids. Biochim. Biophys. Acta. 1190:1994;115-122.
95. Grubauer G., Feingold K.R., Harris R.M., Elias P.M. Lipid content and lipid type as determinants of the epidermal permeability barrier. J. Lipid Res. 30:1989;89-96.
96. Papahadjopoulos D., Jacobson K., Nir S., Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim. Biophys. Acta. 311:1973;330-348.
97. Cornwell P.A., Barry B.W., Stoddart C.P., Bouwstra J.A. Wide-angle X-ray diffraction of human stratum corneum: effects of hydration and terpene enhancer treatment. J. Pharm. Pharmacol. 46:1994;938-950.
98. Takeuchi Y., Yasukawa H., Yamaoka Y., Takahashi N., Tamura C., Morimoto Y., Fukushima S., Vasavada R.C. Effects of oleic acid/propylene glycol on rat abdominal stratum corneum: lipid extraction and appearance of propylene glycol in the dermis measured by fourier transform infrared/attenuated total reflectance (FT-IR/ATR) spectroscopy. Chem. Pharm. Bull. 41:1993;1434-1437.
99. Ogiso T., Iwaki M., Bechako K., Tsutsumi Y. Enhancement of percutaneous absorption by laurocapram. J. Pharm. Sci. 81:1992;762-767.
100. Goates C.Y., Knutson K. Enhanced permeation of polar compounds through human epidermis. I. Permeability and membrane structural changes in the presence of short chain alkohols. Biochim. Biophys. Acta. 1195:1994;169-179.
101. Clancy M.J., Corish J., Corrigan O.I. A comparison of the effects of electrical current and penetration enhancers on the properties of human skin using spectroscopic (FTIR) and calorimetric (DSC) methods. Int. J. Pharm. 105:1994;47-56.
102. Oakeson R., Goates C.Y., Knutson K. Selective extraction of stratum corneum components to probe mechanisms of enhanced percutaneous penetration. J. Control. Release. 28:1994;277-278.
103. Berner B., Mazzenga G.C., Otte J.H., Steffens R.J., Juang R.-H., Ebert C.D. Ethanol: water mutually enhanced transdermal therapeutic system II: skin permeation of ethanol and nitroglycerin. J. Pharm. Sci. 78:1989;402-407.
104. Ghanem A.-H., Mahmoud H., Higuchi W.I., Rohr U.D., Borsadia S., Liu P., Fox J.L., Good W.R. The effects of ethanol on the transport of β-Estradiol and other permeants in hairless mouse skin. II. A new quantitative approach. J. Control. Release. 6:1987;75-83.
105. Oertel R.P. Protein conformational changes induced in human stratum corneum by organic sulfoxides: an infrared spectroscopic investigation. Biopolymers. 16:1977;2329-2345.
106. Goates C.Y., Knutson K. Enhanced permeation and stratum corneum structural alterations in the presence of dithiothreitol. Biochim. Biophys. Acta. 1153:1993;289-298.
107. Eder I., Müller-Goymann C.C. In vivo amino acid extraction from human stratum corneum as indicator for penetration enhancing properties of oleic acid and isopropylmyristate. Pharm. Pharmacol. Lett. 1:1995;14-17.
108. Wotton P.K., Mollgaard B., Hadgraft J., Hoelgaard A. Vehicle effect on topical drug delivery. III. Effect of Azone on the cutaneous permeation of metronidazole and propylene glycol. Int. J. Pharm. 24:1985;19-26.
109. Cooper E.R. Increased skin permeability for lipophilic molecules. J. Pharm. Sci. 73:1984;1153-1156.
110. Katz D., Touitou E. Enhanced skin penetration of prazosin by transcutol-oleic acid mixture. Proc. Int. Symp. Control. Release Bioact. Mater. 18:1991;533-534.
111. Saettone M.F., Monti D., Giannaccini B., Galli-Angeli D. Enhancement of transdermal penetration of dapiprazole through hairless mouse skin. Proc. Int. Symp. Control. Release Bioact. Mater. 18:1991;309-310.
112. Takayama K., Nagai T. Limonene and related compounds as potential skin penetration promoters. Drug Dev. Ind. Pharm. 20:1994;677-684.
113. Hori M., Satoh S., Maibach H.I. Classification of percutaneous penetration enhancers: a conceptional diagram. J. Pharm. Pharmacol. 42:1990;71-72.
114. Pfister W.R., Hsieh D.S.T. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations. Pharm. Technol. 14:1990;132-140.
115. Flynn G.L., Yalkowsky S.H., Roseman T.J. Mass transport phenomena and models: theoretical concepts. J. Pharm. Sci. 63:1974;479-510.
116. Friend D.R. In vitro skin permeation techniques. J. Control. Release. 18:1992;235-248.
117. Haigh J.M., Smith E.W. The selection and use of natural and synthetic membranes for in vitro diffusion experiments. Eur. J. Pharm. Sci. 2:1995;311-330.
118. Roy S.D., de Groot J.S. Percutaneous absorption of nafarelin acetate, an LHRH analog, through human cadaver skin and monkey skin. Int. J. Pharm. 110:1994;137-145.
119. Coutel-Egros A., Maitani Y., Veillard M., Machida Y., Nagai T. Combined effects of pH, co-solvent and penetration enhancers on the in vitro buccal absorption of propranolol through excised hamster cheek pouch. Int. J. Pharm. 84:1992;117-128.
120. Araki M., Yamashita S., Nadai T., Masada M., Kurosaki Y., Nakayama T., Kimura T. Interaction of percutaneous absorption enhancer with stratum corneum of hamster cheek pouch; an electrophysiological study. Int. J. Pharm. 81:1992;39-47.
121. S. Collier, J. Storm, R.L. Bronaugh, Cutaneous metabolism, in: R.L. Bronaugh, H.I. Maibach (Eds.), In Vitro Percutaneous Absorption: Principles, Fundamentals and Applications, CRC Press, Boca Raton, FL, 1991, pp. 67-83.
122. U. Täuber, Drug metabolism in the skin: advantages and disadvantages, in: J. Hadgraft, R.H. Guy (Eds.), Transdermal Drug Delivery, Marcel Dekker, New York, 1989, pp. 99-112.
123. R.C. Wester, H.I. Maibach, Percutaneous absorption in man and animal: a perspective, in: V.A. Drill, P. Lazar (Eds.), Cutaneous Toxicity, Academic Press, New York, 1977, pp. 111-126.
124. Catz P., Friend D.R. Transdermal delivery of levonorgestrel. VIII. Effect of enhancers on rat skin, hairless mouse skin, hairless guinea pig skin and human skin. Int. J. Pharm. 58:1990;93-102.
125. Priborsky J., Mühlbachová E. Evaluation of in-vitro percutaneous absorption across human skin and in animal models. J. Pharm. Pharmacol. 42:1990;468-472.
126. Aungst B.J., Blake J.A., Rogers N.J., Hussain M.A. Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation-enhancing vehicles. J. Pharm. Sci. 79:1990;1072-1076.
127. Itoh T., Xia J., Magavi R., Nishihata T., Rytting J.H. Use of shed snake skin as a model membrane for in vitro percutaneous penetration studies: comparison with human skin. Pharm. Res. 7:1990;1042-1047.
128. Itoh T., Magavi R., Casady R.L., Nishihata T., Rytting J.H. A method to predict the percutaneous permeability of various compounds: shed snake skin as a model membrane. Pharm. Res. 7:1990;1302-1306.
129. Bonina F.P., Montenegro L., Micali G., West D.P., Palicharla P., Koch R.L. In vitro percutaneous absorption evaluation of phenobarbital through hairless mouse, adult and premature human skin. Int. J. Pharm. 98:1993;93-99.
130. Roy S.D., Hou S.-Y.E., Witham S.L., Flynn G.L. Transdermal delivery of narcotic analgesics: comparative metabolism and permeability of human cadaver skin and hairless mouse skin. J. Pharm. Sci. 83:1994;1723-1728.
131. Bond J.R., Barry B.W. Hairless mouse skin is limited as a model for assessing the effects of penetration enhancers in human skin. J. Invest. Dermatol. 90:1988;810-813.
132. Bond J.R., Barry B.W. Limitations of hairless mouse skin as a model for in vitro permeation studies through human skin: hydration damage. J. Invest. Dermatol. 90:1988;486-489.
133. Guy R.H. Recent advances in transdermal drug delivery. Ther. Res. 3:1985;1031-1042.
134. Hughes M.F., Fisher H.L., Birnbaum L.S., Hall L.L. Effect of age on the in vitro percutaneous absorption of phenols in mice. Toxicol. Vitro. 8:1994;221-227.
135. W. Schalla, H. Schaefer, Mechanism of penetration of drugs into the skin, in: R. Brandau, B.H. Lippold (Eds.), Dermal and Transdermal Absorption, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1982, pp. 41-70.
136. Dupuis D., Rougier A., Lotte C., Wilson D.R., Maibach H.I. In vivo relationship between percutaneous absorption and transepidermal water loss according to anatomic site in man. J. Soc. Cosmet. Chem. 37:1986;351-357.
137. Matsuzaki K., Imaoka T., Asano M., Miyajima K. Development of a model membrane system using stratum corneum lipids for estimation of drug skin permeability. Biol. Pharm. Bull. 41:1993;575-579.
138. Hatanaka T., Inuma M., Sugibayashi K., Morimoto Y. Prediction of skin permeability of drugs. II. Development of composite membrane as a skin alternative. Int. J. Pharm. 79:1992;21-28.
139. Hatanaka T., Inuma M., Sugibayashi K., Morimoto Y. Prediction of skin permeability of drugs. I. Comparison with artificial membrane. Chem. Pharm. Bull. 38:1990;3452-3459.
140. Kubota K., Maibach H.I. Significance of viable skin layers in percutaneous permeation and its implication in mathematical models: theoretical considerations based on parameters for betamethasone 17-valerate. J. Pharm. Sci. 83:1994;1300-1306.
141. Guy R.H., Hadgraft J. Physicochemical aspects of percutaneous absorption and its enhancement. Pharm. Res. 5:1988;753-758.
142. Roy S.D., Roos E., Sharma K. Transdermal delivery of buprenorphine through cadaver skin. J. Pharm. Sci. 83:1994;126-130.
143. Monteiro-Riviere N.A., Inman A.O., Riviere J.E., McNeill S.C., Francoeur M.L. Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature. Pharm. Res. 10:1993;1326-1331.
144. Riviere J.E., Sage B., Williams P.L. Effects of vasoactive drugs on transdermal lidocaine iontophorese. J. Pharm. Sci. 80:1992;615-620.
145. J. Riviere, In vitro absorption: skin flap model, in: R.L. Bronaugh, H.I. Maibach (Eds.), In Vitro Percutaneous Absorption: Principles, Fundamentals and Applications, CRC Press, Boca Raton, FL, 1991, pp. 207-222.
146. Rogers R.A., Riviere J.E. Pharmacologic modulation of the cutaneous vasculature in the IPPSF. J. Pharm. Sci. 83:1994;1682-1689.
147. Williams P.L., Carver M.P., Riviere J.E. A physiologically relevant pharmacokinetic model of xenobiotic percutaneous absorption utilizing the IPPSF. J. Pharm. Sci. 79:1990;305-311.
148. Riviere J.E., Monteiro-Riviere N., Williams P. IPPSF as an in vitro model for predicting transdermal pharmacokinetics. Eur. J. Pharm. Biopharm. 3:1995;152-162.
149. Kietzmann M., Löscher W., Arens D., Maaß P., Lubach D. The isolated perfused bovine udder as an in vitro model of percutaneous drug absorption: skin viability and percutaneous absorption of dexamethasone, benzoyl peroxide and etofenamate. J. Pharmacol. Toxicol. Methods. 30:1993;75-84.
150. Kietzmann M., Wenzel B., Löscher W., Lubach D., Müller B.W., Blume H. Absorption of isosorbide dinitrate after administration as spray, ointment and microemulsion patch. An in-vitro study using the isolated perfused bovine udder. J. Pharm. Pharmacol. 47:1995;22-25.
151. M. Kietzmann, D. Arens, W. Löscher, D. Lubach, Studies on the percutaneous absorption of dexamethasone using a new in vitro model, the isolated perfused bovine udder, in: R.C. Scott, R.H. Guy, J. Hadgraft, H.E. Boddé (Eds.), Prediction of Percutaneous Penetration, Vol. 2, IBC Technical Services, London, 1991, pp. 519-526.
152. R.C. Wester, H.I. Maibach, In vivo methods for percutaneous absorption measurements, in: R.L. Bronaugh, H.I. Maibach (Eds.), Percutaneous Absorption, Marcel Dekker, New York, 1985, pp. 245-249.
153. Tsai J.-C., Weiner N.D., Flynn G.L., Ferry J. Properties of adhesive tapes used for stratum corneum stripping. Int. J. Pharm. 72:1991;227-231.
154. Vollmer U., Müller B.W., Wilffert B., Peters T. An improved model for studies on transdermal drug absorption in-vivo in rats. J. Pharm. Pharmacol. 45:1993;242-245.
155. Wojciechowski Z., Pershing L.K., Huether S., Leonard L., Burton S.A., Higuchi W.I., Krueger G.G. An experimental SSF on an independent vascular supply for the study of percutaneous absorption. J. Invest. Dermatol. 88:1987;439-446.
156. Pershing L.K., Lambert L.D., Knutson K. Mechanism of ethanol-enhanced estradiol permeation across human skin in vivo. Pharm. Res. 7:1990;170-175.
157. Leopold C.S., Lippold B.C. A new application chamber for skin penetration studies in vivo with liquid preparations. Pharm. Res. 9:1992;1215-1218.
158. Quisno R.A., Doyle R.L. A new occlusive patch system with a plastic chamber. J. Soc. Cosmet. Chem. 34:1983;13-19.
159. Stricker H., Winter G., Leber A. Galenische Faktoren der kutanen Wirkstoffpenetration in vivo. Acta Pharm. Technol. 33:1987;80-88.
160. Wurster D.E., Kramer S.F. Investigation of some factors influencing percutaneous absorption. J. Pharm. Sci. 50:1961;288-293.
161. Leopold C.S. Quantification of depletion effects in solution-type transdermal preparations in vivo. Pharm. Res. 12:1995;S-278.
162. B.W. Barry, Dermatological formulations, Chap. 5, in: Methods for Studying Percutaneous Absorption, Marcel Dekker, New York, 1983, pp. 234-295.
163. H. Wendt, P.J. Frosch, Klinisch-pharmakologische Modelle zur Prüfung von Corticoidexterna, Karger, Basel, 1982, pp. 13-53.
164. Lippold B.C., Teubner A. Einfluß verschiedener Salbengrundlagen auf die Wirkung von Nicotinsäurebenzylester in Lösungssalben. Pharm. Ind. 43:1981;1123-1133.
165. Lippold B.C., Hackemüller D. The influence of skin moisturizers on drug penetration in vivo. Int. J. Pharm. 61:1990;205-211.
166. M. Bach, Einfluß von potentiellen lipophilen Penetrationsbeschleunigern auf die Wirkung von Modellarzneistoffen. Ph.D. Thesis, Düsseldorf, 1995.
167. Goodman M., Barry B.W. Action of penetration enhancers on human skin as assessed by the permeation of model drug 5-fluorouracil and oestradiol I. Infinite dose technique. J. Invest. Dermatol. 91:1988;323-327.
168. Williams A.C., Barry B.W. The enhancement index concept applied to terpene penetration enhancers for human skin and model lipophilic (oestradiol) and hydrophilic (5-fluorouracil) drugs. Int. J. Pharm. 74:1991;157-168.
169. Mahjour M., Mauser B., Rashidbaigi Z., Fawzi M.B. Effect of egg yolk lecithins and commercial soybean lecithins on in vitro skin permeation of drugs. J. Control. Release. 14:1990;243-252.
170. Lee C.K., Uchida T., Kitagawa K., Yagi A., Kim N.-S., Goto S. Relationship between lipophilicity and skin permeability of various drugs from an ethanol/water/lauric acid system. Biol. Pharm. Bull. 17:1994;1421-1424.
171. Takahashi K., Tamagawa S., Katagi T., Yoshitomi H., Kamada A., Rytting J.H., Nishihata T., Mizuno N. In vitro percutaneous transport of sodium diclofenac and diclofenac from oleaginous vehicle. Chem. Pharm. Bull. 39:1991;509-511.
172. 2 agonist N-0923 with and without Azone. Int. J. Pharm. 87:1992;67-72.